Table 4 Clinical trials of first-line regimens containing platinum agents reported in the literature from 2000

Group	Reference	Regimen	N	RR	MST (m)	1 year ^a	2 year ^b
Doublet	Briasoulis et al (2000)	Carbo–P	77	38.7%	13.0	NA	NA
	Voog et al (2000)	Cis–E	22	32%	8.0	NA	NA
	Greco et al (2000a)	Cis–D	26	26%	8.0	40%	28%
		Carbo–D	47	22%	8.0	33%	28%
	Dowell et al (2001)	Carbo–E	17	19%	8.3	26%	NA
	Saghatchian et al (2001)	Cis–E → Cis–E–B–I	30	40%	9.4	NA	28%
		Cis–F	18	44%	16.1	NA	39%
	Culine et al (2002b)	Dx–Cy⇔Cis–E	82	39%	10.0	NA	NA
	Culine et al (2003)	Cis–G	39	55%	8.0	NA	NA
		Cis–Ir	40	38%	6.0	NA	NA
	Park et al (2004)	Cis–P	37	42%	11.0	38%	11%
	El-Rayes et al (2005)	Carbo–P	22	23%	6.5	27%	NA
	Pittman et al (2006)	Carbo–G	51	30.5%	7.8	26%	12%
	Briasoulis et al (2008a)	Ox–Ir	47	13%	9.5	40%	NA
	Pentheroudakis et al (2008)	Carbo–D	47	32%	16.2	NA	NA
	This study	Carbo–Ir	45	41.9%	12.2	44%	27%
Triplet or more	Parnis et al (2000)	Cis–F–Ep	43	23%	5.8	NA	NA
	Greco et al (2000b)	Carb–P–E	71	48%	11.0	48%	20%
	Guardiola et al (2001)	Cis–Dx–Cy	22	50%	10.7	NA	NA
	Macdonald et al (2002)	Cis–F–Mit	31	27%	7.7	28%	10%
	Greco et al (2002)	Carbo–G–P	113	25%	9.0	42%	23%
	Balaña et al (2003)	Cis–G–E	30	36.6%	7.2	26%	NA
	Piga et al (2004)	Carbo–Dx–E	102	26.5%	9.0	35.2%	18.1%
	Greco et al (2004)	Carbo–P–E → G–Ir	111	33%	9.1	35%	16%
	Palmeri et al (2006)	Cis–G–P	33	48.5%	9.6	NA	NA
		Cis–G–V	33	42.3%	13.6	NA	NA
	Schneider et al (2007)	Carb–G–Cape	33	39.4%	7.6	35.6%	14.2%
	Greco et al (2008)	Carbo–P–Bv–Er	51	48%	11.3	NA	NA

B=bleomycin; Bv=bevacizumab; Cape=capecitabine; Carbo=carboplatin; Cis=cisplatin; Cy=cyclophosphamide; D=docetaxel; Dx=doxorubicin; E=etoposide; Ep=epirubicin; Er=erlotinib; F=5-FU; G=gemcitabine; I=ifosfamide; Ir=irinotecan; m=months; Mit=mitomycin C; MST=median survival time; NA=not available; Ox=oxaliplatin; P=paclitaxel; RR=response rate; V=vinorelbine.
^a1 year=1-year survival rate.
^b2 year=2-year survival rate.

Search